ライフサイエンスコーパス: white blood cell count

1 2 laboratory markers (C-reactive protein and white blood cell count).

2 d increased protein with a slightly elevated white blood cell count.

3 a to be afebrile with normal chest x-ray and white blood cell count.

4 telet parameters and 1 associated with total white blood cell count.

5 hen adjusting for FLT3-ITD, NPM1, CEBPA, and white blood cell count.

6 tus, FLT3-ITD/NPM1 molecular-risk group, and white blood cell count.

7 1.1; P<0.001) but not C-reactive protein or white blood cell count.

8 withdrawn because of a transient decrease in white blood cell count.

9 ematopoietic progenitors, and the peripheral white blood cell count.

10 ad paralleled engraftment and an increase in white blood cell count.

11 en cCD20 level and age, lymphocyte count, or white blood cell count.

12 pression by RA SF was correlated with the SF white blood cell count.

13 oglobin and fetal haemoglobin, and decreased white blood-cell count.

14 sma high-density lipoprotein cholesterol and white blood cell counts.

15 etes and lower C-reactive protein levels and white blood cell counts.

16 suppressant FK506 (tacrolimus) decreases CSF white blood cell counts.

17 (30%) patients were afebrile and had normal white blood cell counts.

18 gic laboratory test results were as follows: white blood cell count, 11.2 x10(9)/L (normal range, [4.

19 Optimal thresholds for white blood cell count (11600/microL), absolute neutroph

20 most common grade 3 or 4 toxicities were low white blood cell count (14 [11%] in the CRT plus cetuxim

21 fusion (4.5% compared with 16.4%; P < 0.05), white blood cell count (14.4 +/- 3.3 compared with 15.6

22 Laboratory evaluation revealed leukocytosis (white blood cell count, 15.4 x 10(9)/L; normal range, [3

23 ia (26 [29%]), anaemia (26 [29%]), decreased white blood cell count (17 [19%]), and decreased lymphoc

24 ients), leucopenia (27 [10%]), and decreased white blood cell count (21 [8%]).

25 g/dL), low glucose level (2 mg/dL), and high white blood cell count (330/mm(3); 28% lymphocytes, 56%

26 count (31 [10%] vs 41 [13%]), and decreased white blood cell count (39 [13%] vs 33 [11%]).

27 ucose level (124 vs 134 mg/dL, P = .03), and white blood cell count (6600/muL vs 17 200/muL, P < .001

28 atase, 88.35 U/L (58.94-117.76 U/L); and for white blood cell count, 6890/microL (5700/microL-8030/mi

29 normal range, 12-60 mg/dL), and an elevated white blood cell count (7/mm(3) [0.007 x10(9)/L] in tube

30 (221 +/- 70 vs. 186 +/- 47, p = 0.008), and white blood cell counts (7.7 +/- 2.3 vs. 6.6 +/- 1.9, p

31 (4.9 [4.0-5.8] vs 4.5 [3.7-5.5] mg/dL), and white blood cell count (7000 [5900-8200] vs 6600 [5600-7

32 ees C [IQR (36.7, 38.5)]; P < .01) and lower white blood cell count (8.3 x 1000 cells/muL [IQR, 5.7,

33 ted prediction highlighted by our tool: that white blood cell count--a quantitative trait of the immu

34 We tested the accuracy of the white blood cell count, absolute neutrophil count, and p

35 White blood cell count also provides predictive informat

36 White blood cell count analysis after alpha-radioimmunot

37 ose episodes, 213 had data allowing complete white blood cell count analysis and were included in the

38 White blood cell count and albumin level are the most cl

39 re significantly predicted only by patients' white blood cell count and albumin level.

40 selective inhibitor tofacitinib reduced the white blood cell count and caused leukemic cell apoptosi

41 The white blood cell count and differential were within the

42 se in splenomegaly, one had normalization of white blood cell count and differential, and one became

43 the mean value of several laboratory tests (white blood cell count and hepatic and lipid panels), ye

44 or a formula using age, performance status, white blood cell count and lactate dehydrogenase, separa

45 ence, waist-hip ratio, alanine transaminase, white blood cell count and lower high-density lipoprotei

46 Vaccine responders had higher total white blood cell count and lymphocyte count and were fur

47 e model uses repeatedly measured biomarkers (white blood cell count and lymphocyte percent) to predic

48 ent with 17-DMAG significantly decreased the white blood cell count and prolonged the survival in a T

49 l fluid examination revealed mildly elevated white blood cell count and protein levels.

50 Her white blood cell count and serum markers for ovarian can

51 ubset analysis based on patient age, gender, white blood cell count and specific cause of bacteremia

52 This C. difficile variant elicited higher white blood cell counts and caused disease in younger pa

53 A content is also influenced by platelet and white blood cell counts and estroprogestogen intake.

54 AST and ALT, and negatively correlated with white blood cell counts and fibrinogen in free-ranging d

55 Total white blood cell counts and leukocyte-distribution profi

56 nosuppression, as monitored by reductions in white blood cell counts and lymphocyte proliferation act

57 meters, including hemoglobin levels, red and white blood cell counts and platelet counts and volume.

58 6562 treatment improved survival, normalized white blood cell counts and platelet counts, and markedl

59 e presented more commonly with low to normal white blood cell counts and with myeloid infiltration of

60 challenge blocked symptoms and increases in white-blood-cell counts and serum interleukin 6.

61 subset of patients with FLT3-ITD, only age, white blood cell count, and < 4-log reduction in PB-MRD,

62 ith VAC also have an abnormal temperature or white blood cell count, and be started on a new antimicr

63 scan with high-resolution B-mode ultrasound, white blood cell count, and C-reactive protein values we

64 er at imaging, laboratory parameters such as white blood cell count, and clinical indications such as

65 ture, heart rate, C-reactive protein levels, white blood cell count, and cytokine levels (tumor necro

66 , reticulocyte count, erythropoietin levels, white blood cell count, and differential.

67 ity lipoprotein cholesterol, pulse pressure, white blood cell count, and fibrinogen.

68 er adjustment for age, sex, current smoking, white blood cell count, and fish consumption, each 1-SD

69 r pulse, higher waist-to-hip ratio, elevated white blood cell count, and heart failure.

70 Toxicity analysis included body weight, white blood cell count, and hematocrit.

71 ood-based biomarkers of inflammation, higher white blood cell count, and higher hematocrit levels did

72 patients had more severe neuropathy, higher white blood cell count, and lower endothelium-dependent

73 ere older, had a higher hemoglobin level and white blood cell count, and lower platelet count and ser

74 core, red blood cell transfusion dependency, white blood cell count, and marrow blasts retained indep

75 Age, sex, white blood cell count, and risk group were similar betw

76 ons of C-reactive protein and liver enzymes, white blood cell count, and use of nonaspirin nonsteroid

77 sented with poorer performance status, lower white blood cell counts, and a lower percentage of marro

78 ysis for overall survival, TP53 alterations, white blood cell counts, and age were the only significa

79 4 weeks with massive splenomegaly, elevated white blood cell counts, and anemia.

80 d aldosterone), hepatobiliary enzyme levels, white blood cell counts, and iron homeostasis.

81 Global coagulation assays, white blood cell counts, and molecular marker assays (EL

82 res, such as advanced clinical stage, higher white blood cell counts, and shorter lymphocyte doubling

83 , as evidenced by even larger spleen, higher white blood cell counts, and shorter survival, compared

84 al use of G-CSF in these patients to support white blood cell counts, and suggest that direct targeti

85 ral parasitaemia, haemoglobin concentration, white-blood-cell count, and liver function.

86 ore (age, creatinine clearance, haemoglobin, white-blood-cell count, and previous spontaneous bleedin

87 The MPD was characterized by an elevated white blood cell count, anemia, and thrombocytopenia wit

88 advanced age, elevated serum creatinine and white blood cell count, anemia, non-ST-segment elevation

89 02), bruising (aOR, 3.17; P=.0059), abnormal white blood cell count (aOR, 0.52; P=.0100), and prior a

90 ase activity by 24 hrs and later recovery of white blood cell counts argue against any potential for

91 asgow Coma Scale score, temperature, pH, and white blood cell count as significant predictors of deat

92 We tested serum C-reactive protein and white blood cell counts as potential mediators of asthma

93 Raised white blood cell counts as well as peaks of serum levels

94 in clinical pulmonary infection score, lower white blood cell count at day 14, reduced bacterial resi

95 fecting event-free and overall survival were white blood cell count at diagnosis (< 30 x 10(9)/L vs >

96 for sex, age (<10 years vs >/=10 years), and white blood cell count at diagnosis (<50 x 10(9)/L vs >/

97 and was significantly correlated with higher white blood cell count at diagnosis (P < .001), increase

98 y MRD result and balancing for sex, age, and white blood cell count at diagnosis by method of minimis

99 as no association between age, Ph(+) status, white blood cell count at diagnosis, and CD20 positivity

100 ification of cases by age at diagnosis, sex, white blood cell count at diagnosis, B or T lineage, or

101 20 expression and E2A-PBX, TEL-AML1, ploidy, white blood cell count at diagnosis, or sex.

102 tervals between sample submission, age, sex, white blood cell count at diagnosis, presence of splenom

103 te respiratory, cardiac, and liver function, white blood cell count at least 3 x 10(9) cells per L, p

104 VH4-34(+) patients had greater white blood cell counts at diagnosis (P = .002), lower r

105 high-dose group had significantly lower mean white blood cell counts at months 5 and 6; however, prem

106 wanted side-effects is to reduce the donor's white blood cell count before transfusion.

107 36) and OS (HR, 0.64; P = .02), with initial white blood cell count being the only factor significant

108 d its color and (b) clinical indices (fever, white blood cell count, bilirubin level, liver function

109 ng disease progression significantly reduced white blood cell count, blast cells, splenomegaly, lacta

110 ne were older; were hypertensive; had higher white blood cell count, blood glucose, D-dimer, and seru

111 ay mortality, including serum urea nitrogen, white blood cell count, body mass index, pulse rate, act

112 cases had normal, the other two had elevated white blood cell count, but all of them had elevated CRP

113 sition, increasing both neutrophil and total white blood cell count by 6 hours post-injection.

114 blocks the symptoms and signs and cytokine, white blood cell count, C-reactive protein, and cardiova

115 the ICU including pancreatic stone protein, white blood cell counts, C-reactive protein, interleukin

116 luorescent labeling or Coulter counting, the white blood cell count can be defined directly from a mi

117 Red and white blood cell counts can also be performed on human b

118 atinib had a larger spleen size and a higher white blood cell count compared with those with BCR-ABL1

119 ion and 8 other risk factors, including age, white blood cell count, cytogenetics, and gene mutations

120 serial blood samples analyzed for changes in white blood cell count, cytokine, and stress hormone lev

121 ssure, ultrafiltration rate, phosphorus, and white blood cell count declined (all P<0.001).

122 ng Casp9 or its cofactor Apaf1 developed low white blood cell counts, decreased B-cell numbers, anemi

123 smoking status, alcohol use, servings of FV, white blood cell count, diastolic blood pressure, diabet

124 otably, expected increases in the peripheral white blood cell count did not occur, suggesting lack of

125 factors, including treatment protocol, age, white blood cell count, DNA index, cell lineage, and cen

126 hemoglobin, hematocrit, MCV, and TS and the white blood cell count do not apply to all ethnic groups

127 In this large cohort of APL patients, high white blood cell count emerged as an independent predict

128 With white blood cell count emerging as an important risk fac

129 etry, blood samples analyzed for hemoglobin, white blood cell counts, eosinophil counts and total ser

130 rior descending CA, respectively), and lower white blood cell count, erythrocyte sedimentation rate,

131 urvival (karyotype, performance status, age, white blood cell count), exploratory analysis suggested

132 g T-PLL is associated with higher presenting white blood cell counts, faster tumor cell doubling, and

133 a mean of 3.8% (P<0.002), whereas the total white blood cell count fell 44.0%+/-3.1% (P<0.001).

134 Six biomarkers (white blood cell count, fibrinogen, D-dimer, troponin T,

135 ven percent of patients with CDI had a serum white blood cell count greater than 12 000 cells per muL

136 Conclusions and Relevance: White blood cell count greater than 20000 cells/microL a

137 al bilirubin level greater than 10 mg/dL and white blood cell count greater than 20000 cells/microL.

138 cell count <13 x 10(9)/L) and proliferative (white blood cell count >/=13 x 10(9)/L) CMML.

139 r pseudomembranous colitis within 5 days; or white blood cell count >/=15 000 cells/microL within 1 d

140 te >90 bpm, mean arterial pressure <60 mmHg, white blood cell count >/=15 000 cells/mL, age >60 years

141 onvert to 109 per liter, multiply by 0.001); white blood cell count >/=15000/microL, 27% (95% CI, 18%

142 ly diagnosed high-risk ALL (age >/=10 years, white blood cell count >/=50x10(9) per L, or both) were

143 High-risk patients (those presenting with a white blood cell count >10 x 10(9) cells per L) could re

144 erythrocyte sedimentation rate >15 mm/hour, white blood cell count >10,000, or gonococcal/chlamydial

145 erythrocyte sedimentation rate >15 mm/hour, white blood cell count >10,000, or gonococcal/chlamydial

146 t >10/high-power field (3 points), and urine white blood cell count >10/high-power field (1 point).

147 aboratory abnormality, commonly defined by a white blood cell count >100,000/microL, caused by leukem

148 ls/mm, a hemoglobin level </= 120 g/L, and a white blood cell count >11 g/L within 90 days before the

149 e renal insufficiency included: age, gender, white blood cell count >12,000, prior CABG, congestive h

150 s was defined as a cerebrospinal fluid (CSF) white blood cell count >20 cells/ microL or reactive CSF

151 1 day before being moribund, macaques had a white blood cell count >20,000 cells/ microL.

152 lls/mm3, band count as a percentage of total white blood cell count >5%, age >65 yrs, lower respirato

153 his approach had minimal toxicity with nadir white blood cell counts >2.7 K/microL 2 weeks after HSCT

154 Seventeen patients (42.5%) had CSF white blood cell counts >20/muL (mean, 57/muL), and 27 (

155 Elevated steady-state white blood cell count (> or = 14 x 10(9)/L [14,000/micr

156 OR, 3.9; 95% CI, 1.4-11.1), high peripheral white blood cell count (>10 x 10(9) cells/L; OR, 8.7; 95

157 /m(2) on day 1) added to high-risk patients (white blood cell count, >10 x 10(9)/L), as well as low-r

158 While a quantitative defect in white blood cell count has not been noted, an alteration

159 th poor outcome (CSF culture positivity, CSF white blood cell count, hemoglobin, Glasgow Coma Scale,

160 performance status of two or more, increased white blood cell count, high-risk IPSS score, and higher

161 olic blood pressure, higher C3 levels, lower white blood cell count, higher insulin levels, and renal

162 FLT3 ITDs were associated with higher white blood cell counts, higher peripheral blast percent

163 tors using tricuspid regurgitation velocity, white blood cell count, history of acute chest syndrome,

164 r pulse, higher waist-to-hip ratio, elevated white blood cell count, history of heart failure, diabet

165 s significantly higher in patients with high white blood cell count (HR 2.45, p 0.011), raised serum

166 s: age (hazard ratio [HR], 3.299; P < .001), white blood cell count (HR, 1.910; P = .017), platelet c

167 fectiveness of various strategies to monitor white blood cell count in adult patients with schizophre

168 The proposed platform enabled rapid white blood cell count in low resource settings with a s

169 far there has been no rapid test that allows white blood cell count in low-resource settings.

170 Existing strategies for monitoring white blood cell count in patients taking clozapine, bas

171 acterial infection with better accuracy than white blood cell count in the blood.

172 cholesterol in men, and with higher BMI and white blood cell count in women (differences 0.03-0.06 s

173 We present a phylogenetic analysis of white blood cell counts in primates to test three hypoth

174 ine cell analyzer to determine bacterial and white blood cell counts in the urine.

175 found between groups in nasal RSV quantity, white blood cell counts in tracheal or nasal aspirates,

176 ctive protein, homocysteine, fibrinogen, and white blood cell count, in 7599 never-smoking adults fro

177 ly expressing miR-125b showed an increase in white blood cell count, in particular in neutrophils and

178 vein occlusion, n=1 each; placebo: vomiting, white blood cell count increased, n=1 each).

179 in these animals, with the total peripheral white blood cell counts increasing more than 40-fold rel

180 cant, time-dependent changes in vital signs, white blood cell counts, inflammatory cytokine/cortisol

181 ggesting that arbitrary divisions of CMML by white blood cell counts into "dysplastic" and "prolifera

182 White blood cell count is an important indicator of each

183 Long-term monitoring of white blood cell count is compulsory in patients taking

184 s than 3 cm; 30 (32%) and nine (17%), if the white blood cell count is normal; and 16 (17%) and six (

185 Currently, white blood cell count is primarily conducted in central

186 ygous state (G/G) was associated with higher white blood cell count, larger spleen index, and higher

187 plete blood cell count parameter thresholds: white blood cell count less than 5000/microL, 10% (95% C

188 s allowed additional hydroxyurea to keep the white blood cell count lower than 5 x 10(9)/L.

189 liferative chronic myelomonocytic leukaemia (white blood cell count <13 000/muL), and had anaemia wit

190 ed, CMML is stratified into myelodysplastic (white blood cell count <13 x 10(9)/L) and proliferative

191 Initial CSF white blood cell counts < or =25 cells/microL and protei

192 with frank hypotension, fever, and elevated white blood cell count, many patients can present with c

193 ction, congestive heart failure, hematocrit, white blood cell count, mean corpuscular volume, blood u

194 thnicity, absence of related donor, obesity, white blood cell count more than 100 000 x 10(9)/L, -7/7

195 ) OR (95% CI), 1.66 (1.21-2.29); P = 0.002], white blood cell count more than 16,000 [OR (95% CI), 1.

196 Independent predictors of CCDC were white blood cell count more than 25,000/muL (HR: 1.08, 9

197 lar risk factors, Framingham risk score, and white blood cell counts, MPO levels were significantly a

198 ectiveness of four strategies for monitoring white blood cell count (national strategies used in the

199 the inflammatory markers C-reactive protein, white blood cell count, neopterin, and kynurenine:trypto

200 ultivariate model adjusted for age, sex, and white blood cell count, odds of NA for patients not imag

201 4 vs 0-2 and 5.20 (95% CI, 2.70-10.02) for a white blood cell count of >/=20 000/muL vs <20 000/muL.

202 ry of transplants, an age of <2 years, a CSF white blood cell count of >5 cells/mm(3), or a protein l

203 = 0.001), leukopenia or leukocytosis (total white blood cell count of <4500 or >20000, P = 0.003), p

204 He was found to have an elevated white blood cell count of 12.2 x 10(9)/L (reference rang

205 oratory analyses were notable for a complete white blood cell count of 17000/muL (31% blast cells), a

206 Laboratory findings revealed an elevated white blood cell count of 18 x 10(9)/L.

207 at the presence of LOH was associated with a white blood cell count of 20 x 10(9)/L or higher but was

208 (n = 11), median age of 12 years, and median white blood cell count of 48.8 x 10(9)/L.

209 tologic laboratory investigations revealed a white blood cell count of 6.7 x 10(9), a C-reactive prot

210 Cerebrospinal fluid analysis showed a white blood cell count of 60/muL (to convert to x109 per

211 nfusion of 4 x 10(10) pPBPC/kg, with a total white blood cell count of 90,000, of which 70% were pig

212 sferrin saturation (TS), serum ferritin, and white blood cell count of African-Americans differ from

213 A white blood cell count of less than 10,000/microL decrea

214 analysis of the validation cohort confirmed white blood cell count of more than 20000 cells/microL (

215 The hematocrit, hemoglobin, MCV, TS, and white blood cell counts of African-Americans were lower

216 atients with eosinophil counts (out of total white blood cell count) of 2% or greater (rate ratio 1.2

217 Therefore, monitoring white blood cell count on a regular basis can potentiall

218 globulins vs. late immunotherapy), and a low white blood cell count on the first cerebrospinal examin

219 New biomarkers, beyond a standard white blood cell count or absolute neutrophil count, con

220 t-form PML-RAR alpha (P <.001), but not with white blood cell count or clinical outcome.

221 factor positivity, and inflammatory markers (white blood cell count or cytokine level).

222 Fever, high white blood cell count or immature forms, low Glasgow co

223 halopathy, longer length of stay, and higher white blood cell count or MELD score at discharge.

224 When outcomes were adjusted for the white blood cell count or the relapse risk score, none o

225 04 [95% CI, .006-.23], P < .0001); and lower white blood cell count (OR = 0.93 [95% CI, .89-.97], P <

226 15 per U/L; 95% CI, 1.006-1.024), increasing white blood cell count (OR, 1.22 per 1000/mm(3); 95% CI,

227 ent of Model for End-Stage Liver Disease and white blood cell count (OR, 4.68; 95% CI, 1.80-12.17; P

228 The presence or absence of fever, abnormal white blood cell count, or purulent pulmonary secretions

229 factor-alpha receptor 2, interleukin-6, and white blood cell count), oxidative stress (8-isoprostane

230 Peak oral temperature (p < .05) and white blood cell count (p < .05), and plasma tumor necro

231 1), whereas it was inversely associated with white blood cell count (P < 0.0001).

232 = 0.009), lobar location of ICH (p < 0.001), white blood cell count (p < 0.001), and admission diasto

233 < .001), lower hemoglobin (P = .01), higher white blood cell count (P = .03) and percentage blood bl

234 er (P < .001), and had a higher presentation white blood cell count (P = .04), but not a higher incid

235 cose level, hypertension (each P < .01), and white blood cell count (P = .04).

236 = 0.002), total skin score (P = 0.005), and white blood cell count (P = 0.005) best explained the ch

237 levels (multiple regression, P = 0.019) and white blood cell count (P = 0.032), whereas the number o

238 so with smaller spleen size (P =.004), lower white blood cell count (P =.0006), and lower percentage

239 ssociated with older age (P < .0001), higher white blood cell counts (P < .0001), cytogenetically nor

240 unt, immune complex-dissociated p24 antigen, white blood cell count, packed-cell volume (haematocrit)

241 r both for clinical examination findings and white blood cell count parameters compared with a valid

242 the known BT risk factors, such as age, sex, white blood cell count, percentage of blasts, IPSS progn

243 n hematologic parameters (hemoglobin levels, white blood cell count, percentage of reticulocytes, pla

244 ition, myocardial and serum cytokines, blood white blood cell counts, peritoneal neutrophil recruitme

245 tor settings, abnormal temperature, abnormal white blood cell count, purulent pulmonary secretions de

246 nt and was continued for 5 days or until the white blood cell count reached >75.0 x 10(9) cells/L.

247 The C-reactive protein level and white blood cell count response were decreased at all do

248 Secondary: white blood cell count, SA use, acquired antibiotic resi

249 years) adults, controlling for age, baseline white blood cell count, secondary AML (sAML), and perfor

250 Age, sex, admission white blood cell count, surgical approach (open vs lapar

251 (hematologic/oxygen-carrying capacity), and white blood cell count (systemic inflammation).

252 odel, body mass index, log triglyceride, log white blood cell count, systolic blood pressure, total a

253 d bloodstream infection (a raised peripheral white blood cell count, temperature >37 degrees C, and/o

254 ases of suspected CRBSI (a raised peripheral white blood cell count, temperature >37 degrees C, and/o

255 cases had higher median cerebrospinal fluid white blood cell count than noninfectious etiologies.

256 V patients were more likely to have a normal white blood cell count than the control group (82% vs 52

257 Smokers had higher white blood cell counts than nonsmokers (7.7+/-0.2 versu

258 the agranulocytosis was due to the lifelong white blood cell counts that are now required for clozap

259 hypertension, C-reactive protein level, and white blood cell count, this association remained signif

260 Reversible leukopenia (decline in white blood cell count to <3.0 x 10(9)/L) was more commo

261 Filgrastim increased the white blood cell count to a median peak of 31.7 x 10(9)

262 e, haemoglobin, potassium, sodium, urea, and white blood cell count) using tree models to implement t

263 An abnormal white blood cell count usually results from an infection

264 median oxygen saturation was 93%, and median white blood cell count was 12x10(3) cells/ mu L.

265 The patient's white blood cell count was 6.8 x 10(9)/L.

266 f splenectomy, hepatitis C, smoking, or high white blood cell count was associated with TRV elevation

267 The white blood cell count was determined by measuring the c

268 White blood cell count was normal, and there was no infl

269 l duration (QTc), deceleration capacity, and white blood cell count was not associated with UFP, AMP,

270 was significantly longer in patients with a white blood cell count (WBC) <50 Giga per liter (G/L) (P

271 erum concentrations of CRP, IL-6, MMP-9, and white blood cell count (WBC) and to examine the relation

272 a novel PheWAS using an individual's maximum white blood cell count (WBC) as a continuous measure.

273 microgranular variant [M3v]), and treatment-white blood cell count (WBC) interaction (ATRA/WBC below

274 White blood cell count (WBC) is an important clinical ma

275 blastic leukemia (ALL) defined by age (1-9), white blood cell count (WBC) less than 50 x 10(9)/L (50,

276 eal inflammation, fluid, appendicoliths, and white blood cell count (WBC) were significantly correlat

277 We examined whether a high white blood cell count (WBC), a marker of inflammation,

278 White blood cell count (WBC), C-reactive protein (CRP),

279 he usefulness of indicators for SBI, such as white blood cell count (WBC), C-reactive protein (CRP),

280 , remaining significant on MVA together with white blood cell count (WBC), sex, and age.

281 -reactive protein (CRP), interleukin (IL)-6, white blood cell count (WBC), vascular cell adhesion mol

282 soluble P-selectin (sCD62P) concentrations; white blood cell count (WBC); heart rate; and blood pres

283 HIV RNA, CSF to serum albumin ratio, and CSF white blood cell counts (WBC), neopterin levels, and con

284 No significant differences in sex and white blood cell count were found.

285 th leukemia-free survival, spleen weight, or white blood cell count were identified on 8 chromosomes.

286 S, sex, C-reactive protein >/=0.9 mg/dl, and white blood cell count were independent predictors of re

287 superinfection, and elevated urea level and white blood cell count were independently associated wit

288 ased HF risk (all P<0.05); serum albumin and white blood cell count were not.

289 Her coagulation profile and white blood cell count were within normal limits.

290 ons and fluctuations in cervical and vaginal white blood cell counts were also evaluated at each stud

291 White blood cell counts were elevated (>10 x 10(9)/L) in

292 come in PV, whereas response in platelet and white blood cell counts were predictive of less thromboh

293 White blood cell counts were significantly greater in sp

294 Total peripheral white blood cell counts were statistically significantly

295 in serum concentrations of interleukin 6 and white-blood-cell counts were seen 4-8 h after cold chall

296 Pertinent laboratory values, including white blood cell count, were normal.

297 elevated total protein and a mildly elevated white blood cell count with lymphocytic predominance.

298 The blood of SCD mice had higher white blood cell counts, with an increased percentage of

299 White blood cell count within 24 h of admission for an A

300 s (hemoglobin, hematocrit, reticulocyte, and white blood cell counts) without evidence of graft versu